Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients

Li, Jian; Gong, Jifang; Li, Jie; Gao, Jing; Sun, Naiping; Shen, Lin

doi:10.3748/wjg.v18.i7.698

Cited by 24 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1), a total of 51 studies were evaluated for quality. Nineteen studies were considered to be of sufficient quality for inclusion in analyses (5)(6)(7)(8)(9)(10)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). Most studies were phase II or III clinical trials, though three retrospective and one prospective observational study were included (25,29,32,36).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis for the Association between Overall Survival and Progression-Free Survival in Gastrointestinal Stromal Tumor

Ozer-Stillman¹,

Strand²,

Chang³

et al. 2014

Clin Cancer Res

View full text Add to dashboard Cite

Purpose: Gastrointestinal stromal tumor (GIST) is a relatively rare tumor that is treated with targeted therapies in advanced stages. Randomized clinical trials (RCT) often require long followup and large sample sizes to evaluate overall survival (OS), the gold-standard measure of treatment efficacy. However, changes in therapy following disease progression may complicate survival assessments. Establishing surrogate endpoints may facilitate the drug approval and availability of new efficacious treatments; however, no published studies have investigated this topic in unresectable and/or metastatic GIST.Experimental Design: A systematic literature review identified 14 RCTs and five observational studies of sufficient methodologic quality published between January 1995 and December 2013 (29 treatment arms; 2,189 patients). Weighted linear regression was used to evaluate the relation between median OS and median progression-free survival (PFS) for all arms combined and stratified by treatment line, treatment type, and quality score.Results: Median OS and PFS were positively related with a correlation of 0.91. The association was still moderate (correlation 0.72) after eliminating four influential data points. In stratified analyses, correlation of OS and PFS was greater in later lines of therapy (first line ¼ 0.52; second line ¼ 0.80; third-and laterline ¼ 0.70) and imatinib showed a stronger association (0.91) than other evaluated treatments (À0.26 to 0.69).Conclusion: This analysis identified a strong relationship between median OS and PFS, especially in later lines of therapy. Findings suggest that PFS could serve as a surrogate marker for OS; however, analyses of patient-level data are needed to establish its validity in GIST.

show abstract

Section: Resultsmentioning

confidence: 99%

“…6,9,23,24,[28][29][30]33], and 17 arms evaluated a third-and later-line population (7-10, 25-27, 32, 34). In a stratified analysis, the linear association was strongest for second-line therapy (R 2 ¼ 0.66, r ¼ 0.80) followed by third-and later-line therapy (R 2 ¼ 0.39, r ¼ 0.70; Fig.…”

Section: Analysis By Treatment Linementioning

confidence: 99%

Meta-analysis for the Association between Overall Survival and Progression-Free Survival in Gastrointestinal Stromal Tumor

Ozer-Stillman¹,

Strand²,

Chang³

et al. 2014

Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…These gene mutations play important roles in cancer generation, development, metastasis, and treatment. With the emergence of the target therapy medicine imatinib (Eisenberg and Judson, 2004;Pisters and Colombo, 2011;Joensuu et al, 2012;Li et al, 2012;Miranda et al, 2012), the response and recovery of GIST patients has been greatly improved. However, in a subset of cases, the tumor remains unstable under imatinib treatment, and in a minority of cases, tumor regrowth is observed (Heinrich et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Physical properties of gastrointestinal stromal tumors based on atomic force microscope analysis

Zhao

Zhang²,

Bao³

et al. 2013

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. This study was designed to detect the stiffness of single living gastrointestinal stromal tumor (GIST) cells in vitro using an atomic force microscope as a probe tool. We determined that the stiffness of living GIST cells was 3913 Pa, the stiffness of the membrane was 642 Pa, and the stiffness of the cytoplasm was 17,550 Pa. For comparison, we also determined the stiffness of a normal stomach cell, which was 7374 Pa, and that of in vitro GIST cells after 2 h of exposure, which was 10,680 Pa. Measuring the mechanical properties of individual GIST cells might provide more complementary information for the diagnosis and treatment of GISTs from the perspective of physical characteristics.

show abstract

“…Surgical removal of the lesion may be performed and postoperative imatinib dose should increase when local progression emerged after excluding patient compliance (22,23). In cases of widespread progression, imatinib dose may be increased to 600 mg/day, which may be more appropriate for Chinese patients (24), or the second-line sunitinib may alternatively be administered. If patients show no response to imatinib or sunitinib, regorafenib is recommended as the third-line therapy (25).…”

mentioning

confidence: 99%

Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review

Feng

Liu

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the efficacy and safety of imatinib mesylate in unresectable gastrointestinal stromal tumor (GIST) and to discuss its therapeutic regimen. A patient with unresectable GIST is described, and several key clinical studies are reviewed, including the clinical trials B2222 and S0033, which contain recently reported results of the long-term clinical outcome of imatinib in patients with unresectable or metastatic GIST. The recent results of the two studies demonstrate the long-term efficacy and safety of imatinib for unresectable or metastatic GIST. A positive response to imatinib treatment was observed in the present patient, which is consistent with the data of the B2222 and S0033 trials. However, further long-term, large-scale, multicenter and controlled trials are required to determine the relative efficacy of combining imatinib agents with surgical procedures or administering imatinib alone.

show abstract

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients

Abstract: Imatinib dose escalation to 600 mg/d is more appropriate for Chinese patients and may achieve further survival benefit.

Cited by 24 publications

References 17 publications

Meta-analysis for the Association between Overall Survival and Progression-Free Survival in Gastrointestinal Stromal Tumor

Meta-analysis for the Association between Overall Survival and Progression-Free Survival in Gastrointestinal Stromal Tumor

Physical properties of gastrointestinal stromal tumors based on atomic force microscope analysis

Partial response to imatinib treatment in a patient with unresectable gastrointestinal stromal tumor: A case report and mini literature review

Contact Info

Product

Resources

About